Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. No serious adverse events were tied to the British biotech’s bispecific T-cell engager in a phase 1/2 trial, and ...
Mark Antonio Wright is the executive editor of National Review. Sit back, relax, and catch up on the whirling vortex that is the news cycle in the second Trump era with NR’s The Week newsletter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback